Modifications of aminoglycoside antibiotics targeting RNA

Medicinal Research Reviews

Volumn 27, Issue 3, 2007, Pages 279-316

  Zhou, Jian ^a   Wang, Guannan ^a   Zhang, Li He ^a   Ye, Xin Shan ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Aminoglycoside; Drug discovery; Review; Structure activity relationship; Targeting RNA

Indexed keywords

2 DEOXYSTREPTAMINE; 2,5 DIDEOXYSTREPTAMINE DERIVATIVE; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMINOGLYCOSIDE DERIVATIVE; AZEPANE GLYCOSIDE; CEPHALOSPORIN DERIVATIVE; DEOXYSTRYPTAMINE DERIVATIVE; FRAMYCETIN; GENTAMICIN; GENTAMICIN DERIVATIVE; GLYCOSIDE; GUANIDINOGLYCOSIDE DERIVATIVE; KANAMYCIN A; KANAMYCIN B; KANAMYCIN C; NEAMINE; NEOMYCIN; NEOMYCIN B DERIVATIVE; PAROMAMINE DERIVATIVE; PAROMOMYCIN; PAROMOMYCIN DERIVATIVE; PYRANMYCIN DERIVATIVE; RIBOSOME RNA; TOBRAMYCIN; TOBRAMYCIN DERIVATIVE; UNCLASSIFIED DRUG;

DRUG BINDING; DRUG DESIGN; DRUG STRUCTURE; DRUG TARGETING; NONHUMAN; REVIEW; RNA BINDING; STRUCTURE ACTIVITY RELATION;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; ANTI-RETROVIRAL AGENTS; DRUG DESIGN; DRUG RESISTANCE, MICROBIAL; HEXOSAMINES; HIV; HUMANS; RNA, RIBOSOMAL; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 34247593152     PISSN: 01986325     EISSN: None     Source Type: Journal    
DOI: 10.1002/med.20085     Document Type: Review

References (126)

1. Hermann T. Strategies for the design of drug targeting RNA and RNA-protein complexes. Angew Chem Int Ed 2000;39:1890-1905.
2. Nowakowski J, Jr., Tinoco I. RNA structure and stability. Seminars in Virology 1997;8:153-165.
3. Hermann T. Rational ligand design for RNA: The role of static structure and conformational flexibility in target recognition. Biochimie 2002;84:869-875.
4. Tor Y. RNA and the small molecule world. Angew Chem Int Ed 1999;38:1579-1582.
5. Gallego J, Varani G. Targeting RNA with small-molecule drugs: Therapeutic promise and chemical challenges. Acc Chem Res 2001;34:836-843.
6. Hermann T, Westhof E. Saccharide-RNA recognition. Biopoly 1998;48:155-165.
7. Vicens Q, Westhof E. RNA as a drug target: The case of aminoglycosides. Chem Bio Chem 2003;4:1018-1023.
8. Forge A, Schacht J. Aminoglycoside antibiotics. Audio Neuro Oto 2000;5:3-22.
9. Magnet S, Blanchard JS. Molecular insights into aminoglycoside action and resistance. Chem Rev 2005;105:477-497.
10. Ritter TK, Wong C-H. Carbohydrate-based antibiotics: A new approach to tackling the problem of resistance. Angew Chem Int Ed 2001;40:3508-3533.
11. Ye X-S, Zhang L-H. Aminoglycoside mimetics as small-molecule drugs targeting RNA. Curr Med Chem 2002;9:929-939.
12. Tok JB-H, Bi L. Aminoglycoside and its derivatives as ligands to target the ribosome. Curr Top Med Chem 2003;3:1001-1019.
13. Tor Y. Targeting RNA with small molecules. Chem Bio Chem 2003;4:998-1007.
14. Greenberg WA, Priestley ES, Sears PS, Alper PB, Rosenbohm C, Hendrix M, Hung SC, Wong C-H. Design and synthesis of new aminoglycoside antibiotics containing neamine as an optimal core structure: Correlation of antibiotic activity with in vitro inhibition of translation. J Am Chem Soc 1999;121:6527-6541.
15. Hendrix M, Priestley ES, Joyce GF, Wong C-H. Direct observation of aminoglycoside-RNA interactions by surface plasmon resonance. J Am Chem Soc 1997;119:3641-3648.
16. Hendrix M, Alper PB, Priestley ES, Wong C-H. Hydroxyamines as a new motif for the molecular recognition of phosphodiesters: Implications for aminoglycoside-RNA interactions. Angew Chem Int Ed 1997;36:95-98.
17. Wong C-H, Hendrix M, Manning DD, Rosenbohm C, Greenberg WA. A library approach to the discovery of small molecules that recognize RNA: Use of a 1,3-hydroxyamine motif as core. J Am Chem Soc 1998;120:8319-8327.
18. Rosenbohm C, Berghe DV, Vlietinck A, Wengel J. Parallel synthesis of a small library of novel aminoglycoside analogs based on 2-amino-2-deoxy- D-glucose and D-ribose scaffolds. Tetrahedron 2001;57:6277-6287.
19. Moazed D, Stern S, Noller HF. Rapid chemical probing of conformation in 16S ribosomal RNA and 30S ribosomal subunits using primer extension. J Mol Biol 1986;187:399-416.
20. Vlietinck AJ, Van Hoof L, Totté J, Lasure A, Vanden Berghe D, Rwangabo PC, Mvukiyumwami J. Screening of hundred Rwandese medicinal plants for antimicrobial and antiviral properties. J Ethnopharmacol 1995;46:31-47.
21. Vourloumis D, Winters GC, Takahashi M, Simonsen KB, Ayida BK, Shandrick S, Zhao Q, Hermann T. Novel acyclic deoxystreptamine mimetics targeting the ribosomal decoding site. Chem Bio Chem 2003;4:879-885.
22. Blount KF, Zhao F, Hermann T, Tor Y. Conformational constraint as a means for understanding RNA-aminoglycoside specificity. J Am Chem Soc 2005;127:9818-9829.
23. Jain C, Belasco J. A structural model for the HIV-1 Rev-RRE complex deduced from altered-specificity rev variants isolated by a rapid genetic strategy. Cell 1996;87:115-125.
24. Tan R, Chen L, Buettner JA, Hudson D, Frankel AD. RNA recognition by an isolated a helix. Cell 1993;73:1031-1040.
25. Faber C, Sticht H, Schweimer K, Rosch P. Structural rearrangements of HIV-1 Tat-responsive RNA upon binding of neomycin B. J Biol Chem 2000;275:20660-20666.
26. Hamasaki K, Woo M-C, Ueno A. An aminoglycoside antibiotic, neamine, and its aromatic ring-substituted derivatives as potential inhibitors for HIV-1 RRE-Rev. Tetrahedron Lett 2000;41:8327-8332.
27. Matsumoto C, Hamasaki K, Mihara H, Ueno A. A high-throughput screening utilizing intramolecular fluorescence resonance energy transfer for the discovery of the molecules that bind HIV-1 TAR RNA specifically. Bioorg Med Chem Lett 2000;10:1857-1861.
28. Litovchick A, Lapidot A, Eisenstein M, Kalinkovich A, Borkow G. Neomycin B-arginine conjugate, a novel HIV-1 Tat antagonist: Synthesis and anti-HIV activities. Biochemistry 2001;40:15612-15623.
29. Hamasaki K, Uero A. Aminoglycoside antibiotics, neamine and its derivatives as potent inhibitors for the RNA-protein interactions derived from HIV-1 activators. Bioorg Med Chem Lett 2001;11:591-594.
30. Nunns CL, Spence LA, Slater MJ, Berrisford DJ. Synthesis of neamine libraries for RNA recognition using solution phase chemistry. Tetrahedron Lett 1999;40:9341-9345.
31. Riguet E, Désire J, Baillyb C, Décout J-L. A route for preparing new neamine derivatives targeting HIV-1 TAR RNA. Tetrahedron 2004;60:8053-8064.
32. Fourmy D, Recht MI, Blanchard SC, Puglisi JD. Structure of the A site of Escherichia coli 16S ribosomal RNA complexed with an aminoglycoside antibiotic. Science 1996;274:1367-1371.
33. Vicensl Q, Westhofl E. Crystal structure of paromomycin docked into the eubacterial ribosomal decoding A Site. Structure 2001;9:647-658.
34. Lynch SR, Jr., Gonzalez RL, Puglisi JD. Comparison of X-ray crystal structure of the 30S subunit-antibiotic complex with NMR structure of decoding site oligonucleotide-paromomycin complex. Structure 2003;11:43-53.
35. Carter AP, Clemons WM, Broderswn DE, Morgan-Warren RJ, Wimberly BT, Ramakrishnan V. Functional insights from the structure of the 30S ribosomal subunit and its interactions with antibiotics. Nature 2000;407:340-348.
36. Simonsen KB, Ayida BK, Vourloumis D, Takahashi M, Winters GC, Barluenga S, Qamar S, Shandrick S, Zhao Q, Hermann T. Novel paromamine derivatives exploring shallow-groove recognition of ribosomal-decoding-site RNA. Chem Bio Chem 2002;3:1223-1228.
37. Haddad J, Vakulenko S, Mobashery S. An antibiotic cloaked by its own resistance enzyme. J Am Chem Soc 1999;121:11922-11923.
38. Liu X, Thomas JR, Hergenrother PJ. Deoxystreptamine dimers bind to RNA hairpin loops. J Am Chem Soc 2004;126:9196-9197.
39. Busscher GF, Rutjes FPJT, van Delft FL. 2-Deoxystreptamine: Central scaffold of aminoglycoside antibiotics. Chem Rev 2005;105:775-791.
40. Sucheck SJ, Greenberg WA, Tolbert TJ, Wong C-H. Design of small molecules that recognize RNA: Development of aminoglycosides as potential antitumor agents that target oncogenic RNA sequences. Angew Chem Int Ed 2000;39:1080-1084.
41. Haddad J, Kotra LP, Beatriz L-S, Kim C, Jr., Azucena EF, Liu M, Vakulenko SB, Chow CS, Mobashery S. Design of novel antibiotics that bind to the ribosomal acyltransfer site. J Am Chem Soc 2002;124: 3229-3237.
42. Hanessian S, Kornienko A, Swayzeb EE. Probing the functional requirements of the L-haba side-chain of amikacin - Synthesis, 16S A-site rRNA binding, and antibacterial activity. Tetrahedron 2003;59:995-1007.
43. Russell RJM, Murray JB, Lentzen G, Haddad J, Mobashery S. The complex of a designer antibiotic with a model aminoacyl site of the 30S ribosomal subunit revealed by X-ray crystallography. J Am Chem Soc 2003;125:3410-3411.
44. Park WKC, Auer M, Jaksche H, Wong C-H. Rapid combinatorial synthesis of aminoglycoside antibiotic mimetics: Use of a polyethylene glycol-linked amine and a neamine-derived aldehyde in multiple component condensation as a strategy for the discovery of new inhibitors of the HIV RNA Rev responsive element. J Am Chem Soc 1996;118:10150-10155.
45. Jin E, Katritch V, Olson WK, Kharatisvili M, Abagyan R, Pilch DS. Aminoglycoside binding in the major groove of duplex RNA: The thermodynamic and electrostatic forces that govern recognition. J Mol Biol 2000;298:95-110.
46. Fink BE, Mortensen DS, Stauffer SR, Aron ZD, Katzenellenbogen JA. Novel structural templates for estrogen-receptor ligands and prospects for combinatorial synthesis of estrogens. Chem Biol 1999;6: 205-219.
47. Ding YL, Hofstadler SA, Swayze EE, Griffey RH. An efficient synthesis of mimetics of neamine for RNA recognition. Org Lett 2001;3:1621-1623.
48. Ding YL, Hofstadler SA, Swayze EE, Griffey RH. Efficient synthesis of heterocyclic 2-deoxysteptamine derivatives as RNA binding ligands. Chem Lett 2003;32:908-909.
49. Ding YL, Hofstadler SA, Swayze EE, Risen L, Griffey RH. Design and synthesis of paromomycin-related heterocycle-substituted aminoglycoside mimetics based on a mass spectrometry RNA binding assay. Angew Chem Int Ed 2003;42:3409-3412.
50. Simonsen KB, Ayida BK, Vourloumis D, Winters GC, Takahashi M, Shandrick S, Zhao Q, Hermann T. Piperidine glycosides targeting the ribosomal decoding site. Chem Bio Chem 2003;4:886-890.
51. Brodersen DE, Clemons WM, Carter AP, Morgan-Warren RJ, Wimberly BT, Ramakrishnan V. The structural basis for the action of the antibiotics tetracycline, pactamycin, and hygromycin B on the 30S ribosomal subunit. Cell 2000;103:1143-1154.
52. Ogle JM, Bordersen DE, Clemons WM, Tarry MJ, Carter AP, Ramakrishnan V. Recognition of cognate transfer RNA by the 30S ribosomal subunit. Science 2001;292:897-902.
53. Barluenga S, Simonsen KB, Littlefield ES, Ayida BK, Vourioumis D, Winters GC, Takahashi M, Shandrick S, Zhao Q, Han Q, Hermann T. Rational design of azepane-glycoside antibiotics targeting the bacterial ribosome. Bioorg Med Chem Lett 2004;14:713-718.
54. Vicens Q, Westhof E. Crystal structure of geneticin bound to a bacterial 16S ribosomal RNA A site oligonucleotide. J Mol Biol 2003;326:1175-1188.
55. Vicens Q, Westhof E. Crystal structure of a complex between the aminoglycoside tobramycin and an oligonucleotide containing the ribosomal decoding A site. Chem Biol 2002;9:747-755.
56. Suami T, Nishiyama S, Ishikawa Y, Katsura S. Chemical modification of neamine. Carbohydr Res 1977;53:239-246.
57. Vourloumis D, Winters GC, Simonsen KB, Takahashi M, Ayida BK, Shandrick S, Zhao Q, Han Q, Hermann T. Aminoglycoside-hybrid ligands targeting the ribosomal decoding site. Chem Bio Chem 2005;6:58-65.
58. Vourloumis D, Takahashi M, Winters GC, Simonsen KB, Ayida BK, Barluenga S, Qamar S, Shandrick S, Zhao Q, Hermann T. Novel 2,5-dideoxystreptamine derivatives targeting the ribosomal decoding site RNA. Bioorg Med Chem Lett 2002;12:3367-3372.
59. Chou C-H, Wu C-S, Chen C-H, Lu L-D, Kulkami SS, Wong C-H, Hung S-C. Regioselective glycosylation of neamine core: A facile entry to kanamycin B related analogues. Org Lett 2004;6:585-588.
60. Venot A, Swayze EE, Griffey RH, Boons G-J. Disaccharide mimetics of the aminoglycoside antibiotic neamine. Chem Bio Chem 2004;5:1228-1236.
61. Liang F-S, Wang S-K, Nakatani T, Wong C-H. Targeting RNAs with tobramycin analogues. Angew Chem Int Ed 2004;43:6496-6500.
62. Lukavsky PJ, Otto GA, Lancaster AM, Sarnow P, Puglisi JD. Structures of two RNA domains essential for hepatitis C virus internal ribosome entry site function. Nat Struct Biol 2000;7:1105-1110.
63. Spahn CMT, Kieft JS, Grassucci RA, Penczek PA, Zhou K, Doudna JA, Frank J. Hepatitis C virus IRES RNA-induced changes in the conformation of the 40S ribosomal subunit. Science 2001;291:1959-1962.
64. Jacks T, Power MD, Masiarz FR, Luciw PA, Barr PJ, Varmus HE. Characterization of ribosomal frameshifting in HIV-1 gag-pol expression. Nature 1988;331:280-283.
65. Shtivelman E, Lifshitz B, Gale RP, Canaani E. Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature 1985;315:550.
66. Wong C-H, Liang F-S. Surface plasmon resonance study of RNA-aminoglycoside interaction. Methods Enzymol 2003;362:340-353.
67. Yao S, Sgarbi PWM, Marby KA, Rabuka D, O'Hare SM, Cheng ML, Bairi M, Hu CY, Hwang S-B, Hwang C-K, Ichikawa Y, Searsc P, Sucheck SJ. Glyco-optimization of aminoglycosides: New aminoglycosides as novel anti-infective agents. Bioorg Med Chem Lett 2004;14:3733-3738.
68. Cohen ML. Epidemiology of drug resistance: Implications for a post-antimicrobial era. Science 1992;257:1050-1055.
69. Neu HC. The crisis in antibiotic resistance. Science 1992;257:1064-1072.
70. Chang C-WT, Hui Y, Elcher B, Wang J, Li J, Rai R. Pyranmycins, a novel class of aminoglycosides with improved acid stability: The SAR of D-pyranoses on ring III of pyranmycin. Org Lett 2002;4:6403-6406.
71. Wang J, Li J, Tuttle D, Takemoto JY, Chang C-WT. The synthesis of L-aminosugar and the studies of L-pyranoses on the ring III of pyranmycins. Org Lett 2002;4:3997-4000.
72. Li J, Wang J, Hui Y, Chang C-WT. Exploring the optimal site for modifications of pyranmycins with the extended arm approach. Org Lett 2003;5:431-434.
73. Elchert B, Li J, Wang J, Hui Y, Rai R, Ptak R, Ward P, Takemoto JY, Bensaci M, Chang C-WT. Application of the synthetic aminosugars forglycodiversification: Synthesis and antimicrobial studies of pyranmycin. J Org Chem 2004;69:1513-1523.
74. Li J, Wang J, Czyryca PJ, Chang H, Orsak TW, Evanson R, Chang C-WT. Application of glycodiversification: Expedient synthesis and antibacterial evaluation of a library of kanamycin B analogues. Org Lett 2004;6:1381-1384.
75. Fridman M, Belakhov V, Yaron S, Baasov T. A new class of branched aminoglycosides: Pseudopentasaccharide derivatives of neomycin B. Org Lett 2003;5:3575-3578.
76. Yoshinari K, Yamazaki K, Komiyama M. Oligoamines as simple and efficient catalysts for RNA hydrolysis. J Am Chem Soc 1991;113:5899-5901.
77. Komiyama M, Yoshinari K. Kinetic analysis of diamine-catalyzed RNA hydrolysis. J Org Chem 1997;62:2155-2160.
78. Han MJ, Yoo KS, Kim YH, Chang JY. The catalytic activity of ribose-containing polymers for the hydrolysis of phosphodiester and the cleavage of nucleic acid. Tetrahedron Lett 2002;43:5597-5600.
79. Resistant strains included E. coliXL1(pET9d), Pseudomonas aeuriginosa(ATCC 27853), and SalmonellaVirchow (SV49). E. coli XL1-(pET9d) is an antibiotic-sensitive laboratory strain of E. coli that harbors plasmid pET9d with the cloned orf2 gene, which codes for aminoglycoside kinase APH(3′). P. aeuriginosa is a Gram-negative pathogen. The aph(3′)-IIb gene, which codes for APH(3′), is a chromosomal gene that can be found in many clinical isolates of P. aeruginosa, including the ATCC 27853 strain, and likely accounts at least partly for the resistance of Pseudomonas to aminoglycosides. S. Virchow (SV49) is a clinical multidrug-resistant strain obtained from poultry and found to be resistant to streptomycin, tetracycline, ampicillin, sulfa, kanamycin, and neomycin. The mechanism(s) of resistance of this strain is still unknown.
80. Dixon TC, Meselson M, Guillemin J, Hanna PC. Medical progress: Anthrax. N Engl J Med 1999;341:815-826.
81. Duesbery NS, Vande Woude GF. Anthrax toxins. Cell Mol Life Sci 1999;55:1599-1609.
82. Ascenzi P, Visca P, Ippolito G, Spallarossa A, Bolognesi M, Montecucco C. Anthrax toxin: A tripartite lethal combination. FEBS Lett 2002;531:384-388.
83. Maly DJ, Choong IC, Ellman JA. Combinatorial target-guided ligand assembly: Identification of potent subtype-selective c-Src inhibitors. Proc Natl Acad Sci USA 2000;97:2419-2424.
84. Lee LV, Bower KE, Liang F-S, Shi J, Wu D, Sucheck SJ, Vogt PK, Wong C-H. Inhibition of the proteolytic activity of anthrax lethal factor by aminoglycosides. J Am Chem Soc 2004;126:4774-4775.
85. Pannifer AD, Wong TY, Schwarzenbacher R, Renatus M, Petosa C, Bienkowska J, Lacy DB, Collier RJ, Park S, Leppla SH, Hanna P, Liddington RC. Crystal structure of the anthrax lethal factor. Nature 2001;414:229-233.
86. Fridman M, Belakhov V, Lee LV, Liang F-S, Wong C-H, Baasov T. Dual effect of synthetic aminoglycosides: Antibacterial activity against bacillus anthracis and inhibition of anthrax lethal factor. Angew Chem Int Ed 2005;44:447-452.
87. Athamna A, Massalha M, Athamna M, Nura A, Medlej B, Ofek I, Bast D, Rubinstein E. In vitro susceptibility of Bacillus anthracis to various antibacterial agents and their time - Kill activity. J Antimicrob Chemother 2004;53:247-251.
88. Kirk SR, Luedtke NW, Tor Y. Neomycin-acridine conjugate: A potent inhibitor of Rev-RRE binding. J Am Chem Soc 2000;122:980-981.
89. Lee J, Kwon M, Lee KH, Jeong S, Hyun S, Shin KJ, Yu J. An approach to enhance specificity against RNA targets using heteroconjugates of aminoglycosides and chloramphenicol (or linezolid). J Am Chem Soc 2004;126:1956-1957.
90. Arya DP, Xue L, Tennant P. Combining the best in triplex recognition: Synthesis and nucleic acid binding of a BQQ-neomycin conjugate. J Am Chem Soc 2003;125:8070-8071.
91. Franois B, Szychowski J, Adhikari SS, Pachamuthu K, Swayze EE, Griffey RH, Migawa MT, Westhof E, Hanessian S. Antibacterial aminoglycosides with a modified mode of binding to the ribosomal-RNA decoding site. Angew Chem Int Ed 2004;43:6735-6738.
92. Alper PB, Hendrix M, Sears P, Wong C-H. Probing the specificity of aminoglycoside-ribosomal RNA interactions with designed synthetic analogs. J Am Chem Soc 1998;120:1965-1978.
93. Tor Y, Hermann T, Westhof E. Deciphering RNA recognition: Aminoglycoside binding to the hammerhead ribozyme. Chem Biol 1998;5:R277-R283.
94. Kirk SR, Tor Y. tRNA(Phe) binds aminoglycoside antibiotics. Bioorg Med Chem 1999;7:1979-1991.
95. Michael K, Wang H, Tor Y. Enhanced RNA binding of dimerized aminoglycosides. Bioorg Med Chem 1999;7:1361-1371.
96. Luedtke NW, Liu Q, Tor Y. RNA-ligand interactions: Affinity and specificity of aminoglycoside dimers and acridine conjugates to the HIV-1 Rev response element. Biochemistry 2003;42:11391-11403.
97. Tok JB-H, Dunn LJ, Jean RCD. Binding of dimeric aminoglycosides to the HIV-1 Rev responsive element (RRE) RNA construct. Bioorg Med Chem Lett 2001;11:1127-1131.
98. Tok JB-H, Huffman GR. Enhanced binding of aminoglycoside dimers to a "dimerized" A-Site 16S rRNA construct. Bioorg Med Chem Lett 2000;14:1593-1595.
99. Tok JB-H, Fenke J. Novel synthesis and RNA-binding properties of aminoglycoside dimers conjugated via a naphthalene diimide-based intercalator. Bioorg Med Chem Lett 2001;11:2987-2991.
100. Sucheck SJ, Wong AL, Koeller KM, Boehr DD, Draker K, Sears P, Wright GD, Wong C-H. Design of bifunctional antibiotics that target bacterial rRNA and inhibit resistance-causing enzymes. J Am Chem Soc 2000;122:5230-5231.
101. Agnelli F, Sucheck SJ, Marby KA, Rabuka D, Yao S-L, Sears PS, Liang F-S, Wong C-H. Dimeric aminoglycosides as antibiotics. Angew Chem Int Ed 2004;43:1562-1566.
102. Liu X, Thomas JR, Hergenrother PJ. Deoxystreptamine dimers bind to RNA hairpin loops. J Am Chem Soc 2004;126:9196-9197.
103. Thomas JR, Liu X, Hergenrother PJ. Size-specific ligands for RNA hairpin loops. J Am Chem Soc 2005;127:12434-12435.
104. Liang C-H, Romero A, Rabuka D, Sgarbi PWM, Marby KA, Duffield J, Yao S, Cheng ML, Ichikawa Y, Sears P, Hu C, Hwang S-B, Shuea Y-K, Suchecka SJ. Structureactivity relationships of bivalent aminoglycosides and evaluation of their microbiological activities. Bioorg Med Chem Lett 2005; 15:2123-2128.
105. Luedtke NW, Baker TJ, Goodman M, Tor Y. Guanidinoglycosides: A novel family of RNA ligands. J Am Chem Soc 2000;122:12035-12036.
106. Hui Y, Ptak R, Paulman R, Pallansch M, Chang C-WT. Synthesis of novel guanidine incorporated aminoglycosides, guanidinopyranmycins. Tetrahedron Lett 2002;43:9255-9257.
107. Baker TJ, Luedtke NW, Tor Y, Goodman M. Synthesis and anti-HIV activity of guanidinoglycosides. J Org Chem 2000;65:9054-9058.
108. Luedtke NW, Carmichael P, Tor Y. Cellular uptake of aminoglycosides, guanidinoglycosides, and polyarginine. J Am Chem Soc 2003;125:12374-12375.
109. Frankel AD. Activation of HIV transcription by Tat. Curr Opin Genet Dev 1992;2:293-298.
110. Kingsman SM, Kingsman AJ. The regulation of human immunodeficiency virus type-1 gene expression. Eur J Biochem 1996;240:491-507.
111. O'Brien WA, Sumner-Smith M, Mao SH, Sadeghi S, Zhao J-Q, Chen ISY. Anti-HIV-1 activity of an oligocationic compound is mediated via gp120 V3 interactions. J Virol 1996;70:2825-2831.
112. Huq I, Wang X, Rana TM. Specific recognition of HIV-1 TAR RNA by a D-Tat peptide. Nature Struct Biol 1997;4:881-882.
113. Hamy F, Felder ER, Heizmann G, Lazdins J, Aboul-Ela F, Varani G, Kam J, Klimkait T. An inhibitor of the Tat/TAR RNA interaction that effectively suppresses HIV-1 replication. Proc Natl Acad Sci USA 1997;94:3548-3553.
114. Calnan BJ, Tidor B, Biancalana S, Hudson D, Frankel AD. Arginine-mediated RNA recognition: The arginine fork. Science 1991;252:1167-1171.
115. Cordingley MG, LaFemina RL, Callahan PL, Condra JH, Sardana VV, Graham DJ, Nguyen TM, LeGrow K, Gotlib L, Schlabach AJ, Colonno RJ. Sequence-specific interaction of Tat protein and Tat peptides with the transactivation-responsive sequence element of human immunodeficiency virus type 1 in vitro. Proc Natl Acad Sci USA 1990;87:8985-8989.
116. Tao J, Frankel AD. Electrostatic interactions modulate the RNA-binding and transactivation specificities of the human immunodeficiency virus and simian immunodeficiency virus Tat proteins. Proc Natl Acad Sci USA 1993;90:1571-1575.
117. Litovchick A, Evdokimov AG, Lapidot A. Arginine-aminoglycoside conjugates that bind to HIV transactivation responsive element RNA in vitro. FEBS Letters 1999;445:73-79.
118. Litovchick A, Evdokimov AG, Lapidot A. Aminoglycoside-arginine conjugates that bind TAR RNA: Synthesis, characterization, and antiviral activity. Biochemistry 2000;39:2838-2852.
119. Blount KF, Zhao F, Hermann T, Tor Y. Conformational constraint as a means for understanding RNA-aminoglycoside specificity. J Am Chem Soc 2005;127:9818-9829.
120. Zhao F, Zhao Q, Blount KF, Han Q, Tor Y, Hermann T. Molecular recognition of RNA by neomycin and a restricted neomycin derivative. Angew Chem Int Ed 2005;44:5329-5334.
121. Asensio JL, Hidalgo A, Bastida A, Torrado M, Corzana F, Chiara JL, Garcia-Junceda E, Canada J, Jimenez-Barbero J. A simple structural-based approach to prevent aminoglycoside inactivation by bacterial defense proteins. Conformational restriction provides effective protection against Neomycin-B nucleotidylation by ANT4. J Am Chem Soc 2005;127:8278-8279.
122. Bastida A, Hidalgo A, Chiara JL, Torrado M, Corzana F, Perez-Canadillas JM, Groves P, Garcia-Junceda E, Gonzalez C, Jimenez-Barbero J, Asensio JL. Exploring the use of conformationally locked aminoglycosides as a new strategy to overcome bacterial resistance. J Am Chem Soc 2006; 128: 100-116.
123. Tok JB-H, Rando RR. Simple aminols as aminoglycoside surrogates. J Am Chem Soc 1998;120:8279-8280.
124. Belmont P, Aissaoui A, Hauchecorne M, Oudrhiri N, Petit L, Vigneronl J-P, Lehn J-M, Lehn P. Aminoglycoside-derived cationic lipids as efficient vectors for gene transfection in vitro and in vivo. J Gene Med 2002;4:517-526.
125. Sainlos M, Belmont P, Vigneron J-P, Lehn P, Lehn J-M. Aminoglycoside-derived cationic lipids for gene transfection: Synthesis of kanamycin A derivatives. Eur J Org Chem 2003;15:2764-2774.
126. Grapsas I, Lerner SA, Mobashery S. Conjoint molecules of cephalosporins and aminoglycosides. Arch Pharm Pharm Med Chem 2001;334:295-301.